0HKD Stock Chart & Stats
$41.69
-$0.54(-1.28%)
At close: 4:00 PM EDT
$41.69
-$0.54(-1.28%)
Day’s Range― - ―
52-Week Range$15.38 - $52.69
Previous CloseN/A
Volume210.00
Average Volume (3M)331.00
Market Cap
$2.55B
Enterprise Value$2.37K
Total Cash (Recent Filing)$94.57M
Total Debt (Recent Filing)$20.07M
Price to Earnings (P/E)―
Beta1.36
Next Earnings
Nov 10, 2026EPS Estimate
0.13Next Dividend Ex-DateN/A
Dividend Yield3.09%
Share Statistics
EPS (TTM)-0.67
Shares Outstanding58,671,513
10 Day Avg. Volume294
30 Day Avg. Volume331
Financial Highlights & Ratios
PEG Ratio-2.01
Price to Book (P/B)11.70
Price to Sales (P/S)6.69
P/FCF Ratio-513.89
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$54.00Price Target Upside29.53% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)0.45
Revenue Forecast (FY)$279.56M
Bulls Say, Bears Say
Bulls Say
Strong Revenue Growth And Raised GuidanceSustained revenue growth and a higher full-year outlook indicate expanding demand for AxoGen’s nerve-repair offerings. Continued momentum across multiple clinical markets can improve operating scale, support commercial reinvestment, and strengthen the company’s market position over the next several quarters.
Growing Avance Adoption And Clinical SupportAvance adoption and rapid Breast-market expansion provide evidence that AxoGen is deepening use of its core products rather than relying only on broad market growth. Positive clinical results and rising surgeon participation can reinforce utilization, physician confidence, and longer-term demand.
De-risked Balance Sheet And Positive Cash FlowVery low leverage and a sizable equity base give AxoGen greater flexibility to fund operations and strategic initiatives while it works toward profitability. Positive operating and free cash flow also reduce reliance on borrowing, although continued consistency remains important for durable financial strength.
Bears Say
Continuing GAAP Losses And Margin DeteriorationAxoGen’s attractive revenue growth and gross margin have not yet translated into sustainable GAAP profitability. Continued losses can constrain internally funded investment, weaken shareholder returns, and leave earnings power dependent on successful operating leverage and disciplined expense management.
Gross-Margin And Operating-Expense PressureThe shift toward longer, higher-cost Avance grafts is pressuring gross margin as product mix changes faster than pricing and production initiatives can respond. Elevated commercial spending may support growth, but it can also delay operating leverage and prolong earnings pressure over the next several quarters.
Equity-Funded Acquisition And Integration RiskThe BioCircuit transaction could broaden AxoGen’s portfolio, but funding it with a public share offering may dilute existing ownership. The acquisition also introduces integration demands and execution uncertainty, creating a risk that expected revenue, margin, and earnings benefits take longer to materialize.
AxoGen News
0HKD FAQ
What was AxoGen’s price range in the past 12 months?
AxoGen lowest share price was $15.38 and its highest was $52.69 in the past 12 months.
What is AxoGen’s market cap?
AxoGen’s market cap is $2.55B.
When is AxoGen’s upcoming earnings report date?
AxoGen’s upcoming earnings report date is Nov 10, 2026 which is in 41 days.
How were AxoGen’s earnings last quarter?
AxoGen released its earnings results on Jul 29, 2026. The company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.121 by -$0.001.
Is AxoGen overvalued?
According to Wall Street analysts AxoGen’s price is currently Undervalued.
Does AxoGen pay dividends?
AxoGen pays a Notavailable dividend of $0.285 which represents an annual dividend yield of 3.09%. See more information on AxoGen dividends here
What is AxoGen’s EPS estimate?
AxoGen’s EPS estimate is 0.13.
How many shares outstanding does AxoGen have?
AxoGen has 58,671,513 shares outstanding.
What happened to AxoGen’s price movement after its last earnings report?
AxoGen reported an EPS of $0.12 in its last earnings report, missing expectations of $0.121. Following the earnings report the stock price went up 3.904%.
Which hedge fund is a major shareholder of AxoGen?
Currently, no hedge funds are holding shares in GB:0HKD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
AxoGen Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$54.00 (29.53% Upside)
$54.00 (29.53% Upside)
Blogger Sentiment
Bullish
GB:0HKD Sentiment 67%
Sector Average 64%
Sector Average 64%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
152.68%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
48.39%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
AxoGen
AxoGen, Inc., along with its subsidiaries, specializes in creating and distributing medical devices for the surgical repair of injured or severed peripheral nerves. Their comprehensive product portfolio offers several innovative solutions. The Avance Nerve Graft is a ready-to-use, biologically active human nerve allograft designed to bridge gaps in severed nerves. This avoids the need for a second surgical site for tissue donation, thereby eliminating associated complications. For facilitating the gentle reconnection of severed peripheral nerves, the company offers the AxoGuard Nerve Connector, an extracellular matrix (ECM) derived from porcine submucosa. This same porcine submucosa ECM forms the basis of the AxoGuard Nerve Protector, which is utilized to encase and safeguard damaged peripheral nerves, supporting their reconstruction and preventing unwanted adhesions from surrounding soft tissues. Another ECM product, the AxoGuard Nerve Cap, isolates the nerve end from its environment to help mitigate the formation of painful neuromas. Furthermore, AxoGen provides the Avive Soft Tissue Membrane, a processed human umbilical cord membrane that functions as an absorbable covering for soft tissues, used to separate tissues within the surgical area. An additional tool available is the AxoTouch two-point discriminator, used for evaluating the density of nerve innervation on the skin's surface. These products are supplied to hospitals, surgery centers, and military medical facilities, catering to plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen's market reach extends across the United States, Canada, Germany, the United Kingdom, other European nations, South Korea, and internationally. The company's main operations are situated in Alachua, Florida.
0HKD Company Deck
0HKD Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented strong operational and commercial momentum: robust revenue growth (Q2 +23.1%), a pronounced acceleration in the Breast market (YTD +47%) that materially expanded Avance volume and adoption, growing active surgeon and account metrics, cash balance strength and raised revenue guidance. Offsetting this optimism are near-term margin pressures driven by an accelerated shift in product mix toward longer, higher-cost Avance grafts, increased operating expenses tied to commercial investment, and pending payer decisions (notably Aetna) that could further accelerate adoption but remain unquantified. Management outlined actionable plans (pricing and production efficiency initiatives) but emphasized these will take time to influence 2026 results. Overall, positives (strong top-line, guidance raise, evidence progress, healthy cash position and commercial momentum) outweigh the manageable operational and margin challenges disclosed.View all GB:0HKD earnings summaries0HKD Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
$54.00
▲(29.53% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month










